Search Result

Results for "

A549 xenograft

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (1) Akt (2) Aminopeptidase (1) Anaplastic lymphoma kinase (ALK) (1) Apoptosis (19) Aurora Kinase (1) Autophagy (2) Bacterial (1) Bcl-2 Family (1) BCRP (1) c-Met/HGFR (1) Caspase (3) Complement System (2) Cyclin G-associated Kinase (GAK) (1) DNA Methyltransferase (1) DNA/RNA Synthesis (1) EGFR (4) Epigenetic Reader Domain (4) Farnesyl Transferase (1) Ferroptosis (1) HDAC (2) Histone Demethylase (1) Histone Methyltransferase (1) IFNAR (2) Insulin Receptor (1) Integrin (1) Interleukin Related (2) JAK (1) MDM-2/p53 (3) MEK (1) Microtubule/Tubulin (4) NF-κB (1) P-glycoprotein (1) PARP (1) PPAR (1) PROTACs (5) RAD51 (2) Raf (1) Ras (1) Reactive Oxygen Species (ROS) (2) Reference Standards (1) ROS Kinase (3) STAT (1) TAM Receptor (1) TGF-β Receptor (1) Thymidylate Synthase (1) TNF Receptor (2) Topoisomerase (3)
By Research Areas:	Cancer (40) Cardiovascular Disease (2) Infection (3) Inflammation/Immunology (8) Metabolic Disease (1)

By Targets:

Adrenergic Receptor (1)

Akt (2)

Aminopeptidase (1)

Anaplastic lymphoma kinase (ALK) (1)

Apoptosis (19)

Aurora Kinase (1)

Autophagy (2)

Bacterial (1)

Bcl-2 Family (1)

BCRP (1)

c-Met/HGFR (1)

Caspase (3)

Complement System (2)

Cyclin G-associated Kinase (GAK) (1)

DNA Methyltransferase (1)

DNA/RNA Synthesis (1)

EGFR (4)

Epigenetic Reader Domain (4)

Farnesyl Transferase (1)

Ferroptosis (1)

HDAC (2)

Histone Demethylase (1)

Histone Methyltransferase (1)

IFNAR (2)

Insulin Receptor (1)

Integrin (1)

Interleukin Related (2)

JAK (1)

MDM-2/p53 (3)

MEK (1)

Microtubule/Tubulin (4)

NF-κB (1)

P-glycoprotein (1)

PARP (1)

PPAR (1)

PROTACs (5)

RAD51 (2)

Raf (1)

Ras (1)

Reactive Oxygen Species (ROS) (2)

Reference Standards (1)

ROS Kinase (3)

STAT (1)

TAM Receptor (1)

TGF-β Receptor (1)

Thymidylate Synthase (1)

TNF Receptor (2)

Topoisomerase (3)

By Research Areas:

Cancer (40)

Cardiovascular Disease (2)

Infection (3)

Inflammation/Immunology (8)

Metabolic Disease (1)

Inhibitors & Agonists

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-146462

Anticancer agent 59	Apoptosis ROS Kinase	Cancer
Anticancer agent 59 (compound 11) has inhibitory activity against kinds of cancer cell lines, especially in A549 with IC₅₀ of 0.2 μM. Anticancer agent 59 induces apoptosis and an increase of Ca ²⁺ and ROS in cancer cells. Anticancer agent 59 significantly decreases mitochondrial membrane potential. Anticancer agent 59 can suppress tumor growth in A549 mouse xenograft model .

HY-168300

Antiangiogenic agent 7	Reactive Oxygen Species (ROS) Apoptosis	Inflammation/Immunology Cancer
Antiangiogenic agent 7 (Compound 1) can induce cell apoptosis, increase Reactive Oxygen Species, and inhibit the intracellular enzyme thioredoxin reductase. Antiangiogenic agent 7 has anti-cancer activity, with an IC₅₀ of 0.08-3.5 μM against cervical cancer cells HeLa, prostate cancer cells PC-3, and non-small cell lung cancer A549. Antiangiogenic agent 7 inhibits tumor growth in mouse xenograft models .

HY-146461

Anticancer agent 58	Apoptosis Caspase ROS Kinase	Cancer
Anticancer agent 58 (compound 16) has inhibitory activity against kinds of cancer cell lines, especially in A549 and T24 with IC₅₀s of 0.6 μM and 0.7 μM, respectively. Anticancer agent 58 induces apoptosis by activating caspase 3/8/9 activity, and induces an increase of Ca ²⁺ and ROS in cancer cells. Anticancer agent 58 significantly decreases mitochondrial membrane potential. Anticancer agent 58 can suppress tumor growth in T24 mouse xenograft model .

HY-P10988

LVTX-8	Apoptosis MDM-2/p53 Integrin	Cancer
LVTX-8 is a peptide toxin, exacted from Lycosa vittata. LVTX-8 has potent anticancer and and anti-metastasis activities towards lung cancer with strong cytotoxicity. LVTX-8 significantly induces apoptosis and inhibits the proliferation, invasion and migration of lung cancer cells through P53 hypoxia pathways and integrin signaling. LVTX-8 significantly inhibits the tumor growth and metastasis in A549/H460 xenograft mice model .

HY-162098

PROTAC tubulin-Degrader-1	PROTACs Microtubule/Tubulin Apoptosis	Cancer
PROTAC tubulin-Degrader-1 is a α/β/β3-tubulin PROTAC degrader. PROTAC tubulin-Degrader-1 exhibits potent anti-proliferative activity against multiple human tumor cell lines. PROTAC tubulin-Degrader-1 induces G2/M phase arrest and apoptosis and inhibits colony formation in A549 and A549/Taxol cells. PROTAC tubulin-Degrader-1demonstrates potent anti-tumor efficacy in A549 and A549/Taxol (Taxol-resistant) xenograft model. PROTAC tubulin-Degrader-1 can be used for the study of non-small cell lung cancer (NSCLC). (Pink: Tubulin ligand (HY-N2146), Blue: CRBN Ligand (HY-10984), Black: Linker (HY-N6056)) .

HY-163363

β-AR antagonist 2	Adrenergic Receptor	Cancer
β-AR antagonist 2 (compound 43) is an antagonist of β-AR (IC₅₀: 0.17 μM). β-AR-IN-1 inhibits the growth of mouse A549 xenograft tumors and shows cardioprotective efficacy against DOX-induced HF in C57 mice .

HY-126180

BAY-866	MEK	Cancer
BAY-866, a sulfamide campound, is an allosteric MEK1 inhibitor with an IC₅₀ of 14 nM. BAY-866 inhibits cell growth of A375 (BRAF) and HCT116 (K-Ras) with IC₅₀s of 13 nM and 277 nM, respectively. BAY-866 inhibits tumor growth in K-Ras-mutated A549 xenograft model .

HY-149352

DG1	Thymidylate Synthase	Cancer
DG1 (Compound 8Nc) is a Thymidylate Synthase (TS) inhibitor that affects cancer angiogenesis and metabolic reprogramming in NSCLC cells. DG1 can effectively inhibit the expression of CD26, ET-1, FGF-1 and EGF. DG1 also effectively inhibits the proliferation of cancer tissue in the A549 xenograft mouse model .

HY-125158

HOI-07	Aurora Kinase Apoptosis	Cancer
HOI-07 is a selective Aurora B kinase inhibitor. HOI-07 blocks phosphorylation of histone H3 on Ser10 in lung cancer cells. HOI-07 induces cell-cycle arrest, and apoptosis. HOI-07 has antitumor activity, and suppresses the tumor growth of A549, 143B and KHOS xenografts .

HY-158156

NF-κB-IN-16	NF-κB Apoptosis	Cancer
NF-κB-IN-16 (compound 9) is a complex (Pt(IV) complex) of NF-κB inhibitor and Cisplatin (HY-17394), which has high efficacy and low toxicity in anti-tumor activity. active. NF-κB-IN-16 can cause DNA damage, induce mitochondrial dysfunction, produce reactive oxygen species, and induce apoptosis through the mitochondrial pathway and endoplasmic reticulum stress. NF-κB-IN-16 potently inhibits the NF-κB/MAPK signaling pathway and disrupts PI3K/AKT signaling. NF-κB-IN-16 also exhibits excellent in vivo antitumor efficiency and low toxicity in A549 or A549/CDDP xenograft models .

HY-156110

IGF2BP1-IN-1	Insulin Receptor	Cancer
IGF2BP1-IN-1 (Compound A11) is a IGF2BP1 inhibitor and inhibits downstream signaling. IGF2BP1-IN-1 binds to IGF2BP1 protein with a K_D value of 2.88 nM. IGF2BP1-IN-1 inhibits cancer cells proliferation (IC₅₀: 9 nM for A549 cell, 34 nM for HCT116). IGF2BP1-IN-1 induces cancer cell apoptosis. GF2BP1-IN-1 inhibits tumor growth in A549 xenograft mouse model .

HY-12757

YHO-13177 2 Publications Verification	BCRP	Cancer
YHO-13177, a acrylonitrile derivative, is an orally active, potent and specific inhibitor of breast cancer resistance protein (BCRP) and ABCG2 with an IC₅₀ value of 10 nM. YHO-13177 potentiates the cytotoxicity of SN-38 in HCT116 and A549 cells that express BCRP. YHO-13177 combined with Irinotecan (HY-16562) significantly suppresses the tumor growth in an HCT116/BCRP xenograft model .

HY-161628

Tapcin	Topoisomerase	Cancer
Tapcin is a dual inhibitor for topoisomerase I and topoisomerase II, with IC₅₀ of 203 and 71 nM. Tapcin inhibits proliferations of cancer cells A-375, HeLa, Huh7.5, U2-OS, A549, Caco-2 and HT29, with IC₅₀s of 441, 1.04, 40.5, 0.002, 0.006, 0.287 and 0.842 nM, respectively. Tapcin exhibits antitumor activity in HT29 xenograft model .

HY-146432

Antitumor agent-60	Apoptosis Raf Ras ROS Kinase MDM-2/p53	Cancer
Antitumor agent-60 (compound 20) is a potent antitumor agent, targeting RAS-RAF signaling pathway and binding to CRAF with a K_d value of 3.93 μM. Antitumor agent-60 induces apoptosis by blocking cell cycle at G2/M phase. Antitumor agent-60 enhances the level of p53 and ROS. Antitumor agent-60 causes oval and irregular nucleus in cancer cells. Antitumor agent-60 can suppress the growth of tumor to some extent in A549 xenograft model .

HY-N7694

Isotoosendanin	TGF-β Receptor JAK STAT Apoptosis	Inflammation/Immunology Cancer
Isotoosendanin is an orally active TGFβR1 inhibitor and abrogating its kinase activity (IC₅₀ = 6732 nM). Isotoosendanin inhibits the JAK/STAT3 signaling pathway by directly targeting SHP-2, enhancing its stability, and reducing its ubiquitination. Isotoosendanin inhibits TGF-β-induced reduces the migration, invasion, and metastasis in triple-negative breast cancer (TNBC) cells. Isotoosendanin exhibits anti-tumor efficacy in TNBC xenograft models and A549 xenograft tumors. Isotoosendanin exhibits significant anti-inflammatory effects in acetic acid-induced vascular permeability and λ-carrageenan-induced hind paw edema tests. Isotoosendanin can be used for the study of non-small cell lung cancer (NSCLC), TNBC and inflammation .

HY-175206

P-gp-IN-30	P-glycoprotein	Cancer
P-gp-IN-30 (Compound 13) is a P-glycoprotein (P-gp) inhibitor by targeting YB-1. P-gp-IN-30 significantly enhances sensitivity to Paclitaxel by reducing total YB-1 and nucleus YB-1 protein expression, inhibiting the expression and function of downstream P-gp, further suppressing the efflux rate of Paclitaxel. P-gp-IN-30 potently inhibits tumor growth in A549/Taxol xenografts mice model with combination of Paclitaxel (HY-B0015). P-gp-IN-30 can be used for non-small cell lung cancer (NSCLC) research .

HY-163434

PRMT5/EGFR-IN-1	EGFR Histone Methyltransferase	Cancer
PRMT5/EGFR-IN-1 (Compound 10p) is an orally active dual PRMT5/EGFR inhibitor, with IC₅₀s of 15.47 and 19.31 μM, respectively. PRMT5/EGFR-IN-1 exhibits antiproliferative activity against A549, MCF7, HeLa, and MDA-MB-231 cell lines. PRMT5/EGFR-IN-1 has favorable in vivo PK and PD properties. PRMT5/EGFR-IN-1 can significantly inhibit the growth of MCF7 orthotopic xenograft tumors .

HY-170968

EGFR-IN-150	EGFR Apoptosis	Cancer
EGFR-IN-150 is an EGFR inhibitor that effectively suppresses the phosphorylation of mutant epidermal growth factor receptor (EGFR) and its downstream AKT signaling pathway, thereby exerting antitumor effects and inducing HMOX1 expression to trigger ferroptosis. EGFR-IN-150 exhibits an IC₅₀ of 0.386 μM against the non-small cell lung cancer (NSCLC) cell line H1975, and significantly inhibits colony formation and migration of both H1975 and A549 cells while inducing apoptosis. In addition, EGFR-IN-150 markedly suppresses tumor growth in the H1975 cell-derived xenograft (CDX) mouse model. EGFR-IN-150 holds promise for research related to non-small cell lung cancer .

HY-P10819

S9-CMC1 TFA	Histone Demethylase Apoptosis	Cancer
S9-CMC1 TFA is a covalent peptide lysine-specific demethylase 1 (LSD1) inhibitor with an IC₅₀ value of 2.53 μM. S9-CMC1 TFA specifically recognizes Cys360 in the enzyme-active region. S9-CMC1 TFA inhibits LSD1 activity, increasing H3K4me1 and H3K4me2 levels, leading to G1 cell cycle arrest and apoptosis and inhibiting cell proliferation. S9-CMC1 TFA significantly inhibits tumor growth in A549 xenograft animal models .

HY-149092

Anticancer agent 109	TAM Receptor	Cancer
Anticancer agent 109 (compound 6-15) is an inhibitor of the Gas6-Axl axis with anti-cancer activity. Anticancer agent 109 inhibits the expression of Gas6 and Axl, and the expression p-PI3K and p-AKT in cancer cells, leads to G1 phase arrest and promotes cancer cells apoptosis, and inhibits tumor growth significantly in nude mouse tumor bearing models .

HY-158331

Gal-ARV-771	PROTACs Epigenetic Reader Domain Apoptosis	Cancer
Gal-ARV-771, PROTAC prodrug, is a gal modified ARV-771 (HY-100972). Gal-ARV-771 can be activated in SA-β-Gal-expressed cancer senescent cells to release ARV-771. Gal-ARV-771 induces selective degradation of BRD4 protein by the ubiquitin-proteasome pathway in senescent cells. Gal-ARV-771 promotes apoptosis of senescent cancer cells .

HY-145828

Microtubule inhibitor 2	Microtubule/Tubulin Ferroptosis	Cancer
Microtubule inhibitor 2 is a potent and selective, orally active microtubule inhibitor. Microtubule inhibitor 2 triggers cell death through ferroptosis . Microtubule inhibitor 2 shows antitumor activity .

HY-151504

Engasertib 1 Publications Verification ALM301	Akt	Cancer
Engasertib is an orally active highly specific AKT inhibitor with IC₅₀ values of 0.13 µM, 0.09 µM and 2.75 µM for AKT1, AKT2 and AKT3, respectively. Engasertib inhibits AKT phosphorylation and modulates downstream signalling in vitro. Engasertib can inhibit cancer cell proliferation and tumor growth .

HY-156568A

SMD-3040 TFA	PROTACs Epigenetic Reader Domain	Cancer
SMD-3040 TFA is a potent and selective SMARCA2 PROTAC degrader (DC₅₀: 12 nM; D_max: 91%). SMD-3040 TFA can inhibit tumor cell proliferation and exhibits antitumor activity. SMD-3040 TFA can be used in the study of tumors such as melanoma . (SMARCA2/4-ligand (HY-171765); HY-112078 VHL ligand (HY-112078))

HY-156568B

SMD-3040 formate	PROTACs Epigenetic Reader Domain	Cancer
SMD-3040 formate is a potent and selective SMARCA2 PROTAC degrader (DC₅₀: 12 nM; D_max: 91%). SMD-3040 formate can inhibit tumor cell proliferation and exhibits antitumor activity. SMD-3040 formate can be used in the study of tumors such as melanoma . (SMARCA2/4-ligand (HY-171765); HY-112078 VHL ligand (HY-112078))

HY-156568

SMD-3040	PROTACs Epigenetic Reader Domain	Cancer
SMD-3040 is a potent and selective SMARCA2 PROTAC degrader (DC₅₀: 12 nM; D_max: 91%). SMD-3040 can inhibit tumor cell proliferation and exhibits antitumor activity. SMD-3040 can be used in the study of tumors such as melanoma . (SMARCA2/4-ligand (HY-171765); HY-112078 VHL ligand (HY-112078))

HY-50683

JNJ-38877605 5 Publications Verification	c-Met/HGFR	Metabolic Disease Cancer
JNJ-38877605 is an orally active ATP-competitive inhibitor of c-Met with an IC₅₀ of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases . JNJ-38877605 inhibits c-Met phosphorylation and regulates lipid accumulation. JNJ-38877605 can be used for tumor and metabolic disease reseach .

HY-149410

MSN8C	Topoisomerase	Cancer
MSN8C, an analog of mansonone E, is a novel catalytic inhibitor of human DNA topoisomerase II. MSN8C induces cancer cell apoptosis. MSN8C shows significant anti-tumor cell proliferation activity in vitro .

HY-162227

Antitumor agent-138	Microtubule/Tubulin Apoptosis	Cancer
Antitumor agent-138 (compound 5b) is an inhibitor against tubulin polymerization at tubulin colchicine-binding sites, with IC₅₀ of 1.87 μM. Antitumor agent-138 arrests the cell cycle at G2/M phase and induces an apoptosis in MCF-7 cells. Antitumor agent-138 inhibits cells migration and angiogenesis .

HY-151155

ALK-IN-23	Anaplastic lymphoma kinase (ALK)	Cancer
ALK-IN-23 is a potent ALK inhibitor with IC₅₀ values of 1.6 nM, 0.71 nM and 1.3 nM for ALK ^WT, ALK ^L1196M and ALK ^G1202R. ALK-IN-23 can block cell cycle in G2 phase and induce apoptosis. ALK-IN-23 inhibits cancer cell migration and colony formation in vitro. ALK-IN-23 exhibits antitumor activity in H2228 xenograft nude mice model with hypotoxicity .

HY-N2150

Psammaplin A	HDAC DNA Methyltransferase DNA/RNA Synthesis Bacterial Aminopeptidase Farnesyl Transferase PPAR Apoptosis	Infection Inflammation/Immunology Cancer
Psammaplin A is a marine metabolite. Psammaplin A is a selective HDAC1 (IC₅₀: 45 nM), DNA methyltransferases (IC₅₀: 18.6 nM) and aminopeptidase N (APN) (IC₅₀: 18 μM) inhibitor. Psammaplin A also inhibits DNA topoisomerase and farnesyl protein transferase. Psammaplin A is a PPARγ activator and induces apoptosis. Psammaplin A has antitumor and anti-inflammatory activities. Psammaplin A has antibacterial activity against Gram-positive bacteria and inhibits DNA synthesis and DNA gyrase activity. Psammaplin A inhibits angiogenesis .

HY-115941

HDAC-IN-9	HDAC Microtubule/Tubulin Apoptosis	Cancer
HDAC-IN-9 is a potent and selective tubulin and HDAC dual inhibitor. HDAC-IN-9 inhibits the invasion and migration of A549 cells. HDAC-IN-9 shows potent antitumor and antiangiogenic effect in vitro and in vivo .

HY-N3980R

Guaiol (Standard) Champacol (Standard); Guaiac alcohol (Standard)	Reference Standards Autophagy RAD51	Infection Cardiovascular Disease Inflammation/Immunology Cancer
Guaiol (Standard) is the analytical standard of Guaiol. This product is intended for research and analytical applications. Guaiol is a sesquiterpenoid alcohol with oral activity found in various traditional Chinese medicines, exhibiting biological activities such as anti-proliferative, autophagy-promoting, insecticidal, anti-anxiety, anti-inflammatory, diuretic, and blood pressure-lowering effects. Guaiol induces apoptosis in non-small cell lung cancer cells by regulating the stability of RAD51 through autophagy modulation. Guaiol can also act directly on parasites, inhibiting their growth by affecting the kinetoplast, mitochondrial matrix and plasma membrane of the promastigotes. Guaiol kills amastigotes at an IC50 of 0.01 µg/mL. Guaiol can be used in research related to cancer, infections, cardiovascular diseases, and inflammatory conditions [4]

HY-N10447

Kurzipene D	Apoptosis	Cancer
Kurzipene D (compound 4) is a potent anticancer agent. Kurzipene D induces the apoptosis and arrested the HepG2 cell cycle at S stage. Kurzipene D shows anti-tumor effects using in vivo zebrafish model. Kurzipene D has the property of inhibiting tumor proliferation and migration .

HY-N3980

Guaiol Champacol; Guaiac alcohol	Autophagy RAD51	Infection Cardiovascular Disease Inflammation/Immunology Cancer
Guaiol is a sesquiterpenoid alcohol with oral activity found in various traditional Chinese medicines, exhibiting biological activities such as anti-proliferative, autophagy-promoting, insecticidal, anti-anxiety, anti-inflammatory, diuretic, and blood pressure-lowering effects. Guaiol induces apoptosis in non-small cell lung cancer cells by regulating the stability of RAD51 through autophagy modulation. Guaiol can also act directly on parasites, inhibiting their growth by affecting the kinetoplast, mitochondrial matrix and plasma membrane of the promastigotes. Guaiol kills amastigotes at an IC₅₀ of 0.01 µg/mL. Guaiol can be used in research related to cancer, infections, cardiovascular diseases, and inflammatory conditions ^[4]

HY-P10995

TAT-327	EGFR IFNAR Interleukin Related TNF Receptor Complement System Apoptosis	Inflammation/Immunology Cancer
TAT-327 is cell-penetrating peptide. TAT-327 selectively inserts into cancer cell membranes and shows potent antitumor activity. TAT-327 effectively inhibits cancer cells proliferation, induces apoptosis and disrupts EGFR signal pathway by inhibiting downstream signals (such as IL-2, TNF-α and IFN-γ) expression and the Eps8/EGFR interaction. TAT-327 significantly inhibits tumor growth in HT-29 xenograft mcie models .

HY-177268

Anticancer agent 277	Apoptosis Reactive Oxygen Species (ROS) PARP Caspase Akt	Cancer
Anticancer agent 277 (Compound 4a) is an anticancer agent. Anticancer agent 277 has cytotoxic activities against cancer cells. Anticancer agent 277 significantly inhibits hepatocellular carcinoma cells proliferation via arresting S and G2/M phase cell cycle and induces apoptosis by inducing ROS production and elevating apoptosis-related proteins expression. Anticancer agent 277 potently inhibits tumor growth in HepG2 xenograft mice model .

HY-P10994

Eps8 peptide 327 Eps8(327-335)	EGFR IFNAR Interleukin Related TNF Receptor Complement System Apoptosis	Inflammation/Immunology Cancer
Eps8 peptide 327 is an HLA-A2402-restricted peptide antigen derived from Eps8 protein. Eps8 peptide 327 has potent antitumor activity with significant cytotoxicity. Eps8 peptide 327 effectively inhibits cancer cells proliferation, induces apoptosis* and disrupts EGFR signal pathway by inhibiting downstream signals (such as IL-2, TNF-α and IFN-γ) expression and the Eps8/EGFR interaction. Eps8 peptide 327 significantly inhibits tumor growth in HT-29 xenograft mcie models .

HY-178036

ZM484	MDM-2/p53 Topoisomerase Bcl-2 Family Caspase Cyclin G-associated Kinase (GAK)	Cancer
ZM484 is a potent dual p53-MDM2/TOP1 inhibitor that exhibits antiproliferative and antitumor activity both in vitro and in vivo. ZM484 effectively upregulates p53 and MDM2 proteins and maintains TOP1 inhibitory activity by the release of camptothecin (CPT) and a potent p53-MDM2 inhibitor. ZM484 induces cell cycle arrest and apoptosis by regulating the expression of key apoptosis- and cycle-related proteins, including caspase-3, Bcl-2, and Cyclin B1. ZM484 can be used for colorectal cancer research .

Cat. No.	Product Name	Target	Research Area

HY-P10087

Mouse TREM-1 SCHOOL peptide Mouse TREM-1(213–221), GF9	Peptides	Inflammation/Immunology Cancer
Mouse TREM-1 SCHOOL peptide (Mouse TREM-1(213-221), GF9) targets the interaction between TREM-1 and its signaling partner DAP-12, specifically silencing the TREM-1 signaling pathway, regulate the production of TREM-1-mediated pro-inflammatory cytokines in vivo and in vitro. Mouse TREM-1 SCHOOL peptide has anti-tumor effects. Mouse TREM-1 SCHOOL peptide can reduce the formation of vitreoretinal neovascularization .